June 1, 2018 — Socium Therapeutics, Inc. (“Socium”) announced that it had finalized the acquisition of Aeterna Zentaris’ live recombinant oral allogenic immunotherapy platform (“Platform”), including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase I clinical trial. As part of the acquisition, Socium owns all intellectual property, regulatory dossiers, pre-clinical data and cellular material related to the Platform.

Tim Salmon, Co-founder, President and CEO of Socium, commented, “The Platform, which we refer to as the CReST Platform (Cross-presenting Recombinant Salmonella typhi Ty21a), represents a major step forward in immuno-oncology. The CReST Platform provides for oral delivery; leverages the long, safe human use of S. typhi Ty21a to treat typhoid fever; activates the largest concentration of immune cells in the gut; and induces tumor-antigen-specific killer T-cell activation in vivo. Candidates from the CReST Platform will be tested in up-coming clinical trials as monotherapies and combination therapies (e.g., with checkpoint inhibitors) against a variety of oncology indications.”